Drug Profile
SRN 001
Alternative Names: SRN-001Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator KeyNeurotek AG
- Developer KeyNeurotek Pharmaceuticals AG
- Class Antimigraines; Ergot alkaloids; Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Migraine; Parkinson's disease
Most Recent Events
- 15 Jul 2004 SRN 001 will be available for licensing after successful completion of phase II clinical trials (http://www.sirenade.biz)
- 15 Jul 2004 Phase-I clinical trials in Migraine in Germany (unspecified route)
- 15 Jul 2004 Phase-II clinical trials in Alzheimer's disease in Germany (unspecified route)